Please login to the form below
Symkevi
This page shows the latest Symkevi news and features for those working in and with pharma, biotech and healthcare.
Vertex’s triple combination CF therapy to become available on the NHS
Last October, the three parties finally reached an agreement for access to Vertex’s other cystic fibrosis drugs Orkambi (lumacaftor/ivacaftor), Symkevi (tezacaftor/ivacaftor) and Kalydeco (ivacaftor). ... It’s also great news that more mutations have
Latest news
-
Vertex continues upward trajectory with French Orkambi deal
The American pharma giant reached an agreement with the English regulatory bodies in October, for access to Orkambi and Vertex’s other CF treatments Symkevi (tezacaftor-ivacaftor) and Kalydeco (ivacaftor).
-
Vertex, NHS England and NICE finally reach agreement for Orkambi
Deal also includes Vertex’s other licensed cystic fibrosis medicines
-
Vertex scores FDA approval for CF triple therapy Trikafta
and Symkevi/Symdeko (tezacaftor/ivacaftor) – which can treat around half of patients.
-
Vertex scores CF deal with Scotland, but access debate continues
Scotland to access Orkambi (lumacaftor/ivacaftor) and Symkevi (tezacaftor/ivacaftor).
-
Vertex faces rejection of its CF medicines in Scotland
Another rejection over cost-effectiveness. The Scottish Medicines Consortium (SMC) has not recommended Vertex’s cystic fibrosis drugs Orkambi (lumacaftor/ivacaftor) and Symkevi (tezacaftor/ivacaftor) for routine NHS use in Scotland.
More from news
Approximately 3 fully matching, plus 18 partially matching documents found.
Latest Intelligence
-
Vertex: a vision of treating all CF patients worldwide draws closer
of CF patients and now Symkevi (ivacaftor and tezacaftor). This is effective for people who have two copies of the F508del mutation plus those with one of 14 other mutations.
-
The Orkambi row explained
It refuses to file Symkevi with NICE, stating that it will only submit its data if NICE updates its appraisal process. ... December 2018: Scottish Government agrees a deal with Vertex pending submission of Orkambi and Symkevi to Scottish Medicines
-
The Orkambi blame game
price of its existing CF treatments Kalydeco and Orkambi, as well as new combination Symkevi and any subsequent products.
-
#OrkambiNow?
The US company, based in Cambridge, Massachusetts is a pioneer of groundbreaking ‘precision medicine’ drugs against cystic fibrosis Kalydeco (launched in 2012) and Orkambi (2015) and now Symkevi (2018). ... The hope is that both sides can come to a
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Bristol Myers Squibb announces positive trial results for treatment of MS
- My journey advancing the science in pulmonary hypertension
- A new era for UK-Japanese scientific research relations
- Enanta takes legal action against Pfizer over Paxlovid patent infringement
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- Pfizer and BioNTech share positive results for Omicron-adapted COVID-19 vaccine
- NICE issues final draft recommending Novartis’ Scemblix to treat chronic myeloid leukaemia
- Alzheimer's Research UK supports government plans for clinical research
- GSK announces The HealthTree Foundation’s multiple myeloma programme as first ‘Think Tank’ challenge winner
- NRG Therapeutics partners with Domainex to develop neurodegenerative disease treatment
- Innovative Trials opens first US office
- Scanning for Health Indicators and Risks Through Your Smartphone
- Realising the potential of omnichannel in medical communications
- College of Medicine launches Beyond Pills campaign to tackle overprescribing in UK health system
- AI is transforming pharma R&D – now it can transform pharma marketing
- J&J’s Darzalex shows ‘significant’ survival benefit in newly diagnosed multiple myeloma
- Six UK universities receive grant for research into motor neurone disease
- My journey advancing the science in pulmonary hypertension
PMHub
Graphite Digital
We’re a digital CX agency collaborating with healthcare and pharmaceutical organisations to help them connect more deeply with their audiences...
Latest intelligence
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
